KRAS and neoplasm: Resistant tumours eventually develop in a mouse model of KRAS-driven, p53 mutant NSCLC treated with IKKβ inhibitors after a prolonged period of tumour-free survival [266], but no mechanisms of resistance to IKK/NF-κB inhibitors have been defined to-date.